YHLO Has Green Light for Exportation!

2020-04-28

Summary:YHLO iFlash-SARS-CoV-2 (2019-nCoV) IgM/IgG assays are listed “Name List of Medical Devices and Supplies Companies with Certification / Authorization from other Countries”, issued by China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE).

On 2020 April 28, YHLO iFlash-SARS-CoV-2 (2019-nCoV) IgM/IgG assays are listed “Name List of Medical Devices and Supplies Companies with Certification / Authorization from other Countries”, issued by China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE). It means these products have officially obtained the legal export qualification and YHLO can be fully dedicated to combating the COVID-19 pandemic together with the frontlines all over the world by offering a safe, reliable and efficient detection solution.

http://www.cccmhpie.org.cn/Pub/6325/176181.shtml 

According to Worldometer statistics, as of April 28, the number of coronavirus cases exceeded 3 million and the deaths are more than 200 thousand. The heartbreaking data indicates coronavirus pandemic is really a serious public health risk, thus prevention and control should be priority. China has continuously strengthened supervision over the export of epidemic prevention materials, and has successively issued lists of “Medical Devices and Supplies Companies” and “Non-Medical Use Face Masks Companies” with certification/authorization from other countries, so as to help the global fighting against the pandemic. YHLO products have entered the list because of the outstanding performance.

After the outbreak of novel coronavirus, YHLO initiated the coronavirus specificity research in January, and completed the expression of virus-specific antigen in February, later successfully launched SARS-CoV-2 IgM/IgG assays in high-speed chemiluminescence system. In March, these assays were CE marked and FDA Pre-EUA accepted. YHLO has achieved independent development from core raw materials to finished assays. 

Since then, YHLO SARS-CoV-2 products have been adopted by a number of hospitals and laboratories, including not only Chinese hospitals (such as the famous Huoshenshan Hospital, Fangcang Hospital, Tongji Medical College of Huazhong University of Science and Technology, Hubei General Hospital, District General Hospital of the People's Liberation Army) but also oversea hospitals in Italy, Germany, France, Denmark, Sweden, Japan, Thailand etc., to help diagnosis and screening of COVID-19 infection. The outstanding product performance has attracted a lot of European media attention.

Language
Search
亚辉龙

Join Us

关注我们

Wechat

Headquarter: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China

Follow YHLO

wechatwechat wechat wechat wechat

© 2020  Shenzhen YHLO Biotech Co., Ltd.  All rights reserved.  粤ICP备19040167号